ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT)

Jung Sun Kim, Byeong Kuk Kim, Ik Kyung Jang, Dong Ho Shin, Young Guk Ko, Donghoon Choi, Myeongki Hong, Yun Kyeong Cho, Chang Wook Nam, Seung Ho Hur, Jin Ho Choi, Young Bin Song, Joo Yong Hahn, Seung Hyuk Choi, Hyeon Cheol Gwon, Yangsoo Jang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Data on strut surface coverage of second-generation drug-eluting stents (DES) are limited. We investigated stent strut coverage of resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) at 9 months after implantation using optical coherence tomography (OCT). Methods: ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT) is a prospective, randomized, multicenter trial comparing ZES-R to EES using OCT at 9 months after stent implantation. The primary end point was the rate of stent strut coverage at 9 months. Results: A total of 51 patients were randomized to receive either ZES-R (ZES-R group) or EES (EES group), and 47 stents (24 ZES-R and 23 EES) in 44 of 51 patients were evaluated by OCT both immediately after stent implantation and at 9 months. The neointimal thickness was not significantly different between the 2 groups at 9 months (ZES-R vs EES: 139 ± 58 vs 124 ± 42 μm, P =.31). The mean percentages of uncovered stent struts were 3.3% for ZES-R versus 3.4% for EES at 9 months (P =.51). The proportions of malapposed struts immediately after stent implantation (P =.89) and at 9-month follow-up (P =.34) were 0.8% and 0.7% for ZES-R versus 1.0% and 0.1% for EES, respectively. Thrombi were documented in 1 stent (1 [4.2%] in ZES-R vs 0 [0%] in EES). Conclusion: According to the sequential OCT evaluation, ZES-R and EES showed comparable neointimal thickness and the rate of uncovered stent strut at 9 months after stent implantation.

Original languageEnglish
Pages (from-to)601-607
Number of pages7
JournalAmerican heart journal
Volume163
Issue number4
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Optical Coherence Tomography
Stents
Everolimus
zotarolimus

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Jung Sun ; Kim, Byeong Kuk ; Jang, Ik Kyung ; Shin, Dong Ho ; Ko, Young Guk ; Choi, Donghoon ; Hong, Myeongki ; Cho, Yun Kyeong ; Nam, Chang Wook ; Hur, Seung Ho ; Choi, Jin Ho ; Song, Young Bin ; Hahn, Joo Yong ; Choi, Seung Hyuk ; Gwon, Hyeon Cheol ; Jang, Yangsoo. / ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). In: American heart journal. 2012 ; Vol. 163, No. 4. pp. 601-607.
@article{4a5d7e29825644aba69ac2928f79a09b,
title = "ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT)",
abstract = "Background: Data on strut surface coverage of second-generation drug-eluting stents (DES) are limited. We investigated stent strut coverage of resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) at 9 months after implantation using optical coherence tomography (OCT). Methods: ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT) is a prospective, randomized, multicenter trial comparing ZES-R to EES using OCT at 9 months after stent implantation. The primary end point was the rate of stent strut coverage at 9 months. Results: A total of 51 patients were randomized to receive either ZES-R (ZES-R group) or EES (EES group), and 47 stents (24 ZES-R and 23 EES) in 44 of 51 patients were evaluated by OCT both immediately after stent implantation and at 9 months. The neointimal thickness was not significantly different between the 2 groups at 9 months (ZES-R vs EES: 139 ± 58 vs 124 ± 42 μm, P =.31). The mean percentages of uncovered stent struts were 3.3{\%} for ZES-R versus 3.4{\%} for EES at 9 months (P =.51). The proportions of malapposed struts immediately after stent implantation (P =.89) and at 9-month follow-up (P =.34) were 0.8{\%} and 0.7{\%} for ZES-R versus 1.0{\%} and 0.1{\%} for EES, respectively. Thrombi were documented in 1 stent (1 [4.2{\%}] in ZES-R vs 0 [0{\%}] in EES). Conclusion: According to the sequential OCT evaluation, ZES-R and EES showed comparable neointimal thickness and the rate of uncovered stent strut at 9 months after stent implantation.",
author = "Kim, {Jung Sun} and Kim, {Byeong Kuk} and Jang, {Ik Kyung} and Shin, {Dong Ho} and Ko, {Young Guk} and Donghoon Choi and Myeongki Hong and Cho, {Yun Kyeong} and Nam, {Chang Wook} and Hur, {Seung Ho} and Choi, {Jin Ho} and Song, {Young Bin} and Hahn, {Joo Yong} and Choi, {Seung Hyuk} and Gwon, {Hyeon Cheol} and Yangsoo Jang",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.ahj.2011.10.016",
language = "English",
volume = "163",
pages = "601--607",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

Kim, JS, Kim, BK, Jang, IK, Shin, DH, Ko, YG, Choi, D, Hong, M, Cho, YK, Nam, CW, Hur, SH, Choi, JH, Song, YB, Hahn, JY, Choi, SH, Gwon, HC & Jang, Y 2012, 'ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT)', American heart journal, vol. 163, no. 4, pp. 601-607. https://doi.org/10.1016/j.ahj.2011.10.016

ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). / Kim, Jung Sun; Kim, Byeong Kuk; Jang, Ik Kyung; Shin, Dong Ho; Ko, Young Guk; Choi, Donghoon; Hong, Myeongki; Cho, Yun Kyeong; Nam, Chang Wook; Hur, Seung Ho; Choi, Jin Ho; Song, Young Bin; Hahn, Joo Yong; Choi, Seung Hyuk; Gwon, Hyeon Cheol; Jang, Yangsoo.

In: American heart journal, Vol. 163, No. 4, 01.04.2012, p. 601-607.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT)

AU - Kim, Jung Sun

AU - Kim, Byeong Kuk

AU - Jang, Ik Kyung

AU - Shin, Dong Ho

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Hong, Myeongki

AU - Cho, Yun Kyeong

AU - Nam, Chang Wook

AU - Hur, Seung Ho

AU - Choi, Jin Ho

AU - Song, Young Bin

AU - Hahn, Joo Yong

AU - Choi, Seung Hyuk

AU - Gwon, Hyeon Cheol

AU - Jang, Yangsoo

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: Data on strut surface coverage of second-generation drug-eluting stents (DES) are limited. We investigated stent strut coverage of resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) at 9 months after implantation using optical coherence tomography (OCT). Methods: ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT) is a prospective, randomized, multicenter trial comparing ZES-R to EES using OCT at 9 months after stent implantation. The primary end point was the rate of stent strut coverage at 9 months. Results: A total of 51 patients were randomized to receive either ZES-R (ZES-R group) or EES (EES group), and 47 stents (24 ZES-R and 23 EES) in 44 of 51 patients were evaluated by OCT both immediately after stent implantation and at 9 months. The neointimal thickness was not significantly different between the 2 groups at 9 months (ZES-R vs EES: 139 ± 58 vs 124 ± 42 μm, P =.31). The mean percentages of uncovered stent struts were 3.3% for ZES-R versus 3.4% for EES at 9 months (P =.51). The proportions of malapposed struts immediately after stent implantation (P =.89) and at 9-month follow-up (P =.34) were 0.8% and 0.7% for ZES-R versus 1.0% and 0.1% for EES, respectively. Thrombi were documented in 1 stent (1 [4.2%] in ZES-R vs 0 [0%] in EES). Conclusion: According to the sequential OCT evaluation, ZES-R and EES showed comparable neointimal thickness and the rate of uncovered stent strut at 9 months after stent implantation.

AB - Background: Data on strut surface coverage of second-generation drug-eluting stents (DES) are limited. We investigated stent strut coverage of resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) at 9 months after implantation using optical coherence tomography (OCT). Methods: ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT) is a prospective, randomized, multicenter trial comparing ZES-R to EES using OCT at 9 months after stent implantation. The primary end point was the rate of stent strut coverage at 9 months. Results: A total of 51 patients were randomized to receive either ZES-R (ZES-R group) or EES (EES group), and 47 stents (24 ZES-R and 23 EES) in 44 of 51 patients were evaluated by OCT both immediately after stent implantation and at 9 months. The neointimal thickness was not significantly different between the 2 groups at 9 months (ZES-R vs EES: 139 ± 58 vs 124 ± 42 μm, P =.31). The mean percentages of uncovered stent struts were 3.3% for ZES-R versus 3.4% for EES at 9 months (P =.51). The proportions of malapposed struts immediately after stent implantation (P =.89) and at 9-month follow-up (P =.34) were 0.8% and 0.7% for ZES-R versus 1.0% and 0.1% for EES, respectively. Thrombi were documented in 1 stent (1 [4.2%] in ZES-R vs 0 [0%] in EES). Conclusion: According to the sequential OCT evaluation, ZES-R and EES showed comparable neointimal thickness and the rate of uncovered stent strut at 9 months after stent implantation.

UR - http://www.scopus.com/inward/record.url?scp=84860113127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860113127&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2011.10.016

DO - 10.1016/j.ahj.2011.10.016

M3 - Article

C2 - 22520526

AN - SCOPUS:84860113127

VL - 163

SP - 601

EP - 607

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -